255 related articles for article (PubMed ID: 8458646)
41. Reciprocal feedback regulation of kidney angiotensinogen and renin mRNA expressions by angiotensin II.
Schunkert H; Ingelfinger JR; Jacob H; Jackson B; Bouyounes B; Dzau VJ
Am J Physiol; 1992 Nov; 263(5 Pt 1):E863-9. PubMed ID: 1443118
[TBL] [Abstract][Full Text] [Related]
42. Losartan inhibits the angiotensin II-induced stimulation of the phosphoinositide signalling system in vascular smooth muscle cells.
Ko Y; Görg A; Appenheimer M; Wieczorek AJ; Düsing R; Vetter H; Sachinidis A
Eur J Pharmacol; 1992 Oct; 227(2):215-9. PubMed ID: 1426030
[TBL] [Abstract][Full Text] [Related]
43. Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation.
Lassègue B; Alexander RW; Nickenig G; Clark M; Murphy TJ; Griendling KK
Mol Pharmacol; 1995 Oct; 48(4):601-9. PubMed ID: 7476884
[TBL] [Abstract][Full Text] [Related]
44. Effect of angiotensin II receptor blocker on angiotensin II stimulated DNA synthesis of cultured human aortic smooth muscle cells.
Makita S; Nakamura M; Yoshida H; Hiramori K
Life Sci; 1995; 56(20):PL383-8. PubMed ID: 7723594
[TBL] [Abstract][Full Text] [Related]
45. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174.
Dickinson KE; Cohen RB; Skwish S; Delaney CL; Serafino RP; Poss MA; Gu Z; Ryono DE; Moreland S; Powell JR
Br J Pharmacol; 1994 Sep; 113(1):179-89. PubMed ID: 7812609
[TBL] [Abstract][Full Text] [Related]
46. Expression of components of the RAS during prolonged blockade at different levels in primates.
Samani NJ; Cumin F; Kelly M; Wood JM
Am J Physiol; 1994 Oct; 267(4 Pt 1):E612-9. PubMed ID: 7943312
[TBL] [Abstract][Full Text] [Related]
47. Prolonged angiotensin II antagonism in spontaneously hypertensive rats. Hemodynamic and biochemical consequences.
Bunkenburg B; Schnell C; Baum HP; Cumin F; Wood JM
Hypertension; 1991 Sep; 18(3):278-88. PubMed ID: 1889842
[TBL] [Abstract][Full Text] [Related]
48. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.
Robertson MJ; Barnes JC; Drew GM; Clark KL; Marshall FH; Michel A; Middlemiss D; Ross BC; Scopes D; Dowle MD
Br J Pharmacol; 1992 Dec; 107(4):1173-80. PubMed ID: 1467838
[TBL] [Abstract][Full Text] [Related]
49. A long-term receptor stimulation is requisite for angiotensin II-dependent DNA synthesis in vascular smooth muscle cells from spontaneously hypertensive rats.
Itazaki K; Hara M; Itoh N; Fujimoto M
Eur J Pharmacol; 1995 Nov; 291(3):417-25. PubMed ID: 8719428
[TBL] [Abstract][Full Text] [Related]
50. Effects of losartan, an angiotensin II antagonist, on the development of cardiac hypertrophy due to volume overload.
Ishiye M; Umemura K; Uematsu T; Nakashima M
Biol Pharm Bull; 1995 May; 18(5):700-4. PubMed ID: 7492986
[TBL] [Abstract][Full Text] [Related]
51. The role of the renin-angiotensin system in cisplatin nephrotoxicity.
Deegan PM; Nolan C; Ryan MP; Basinger MA; Jones MM; Hande KR
Ren Fail; 1995 Nov; 17(6):665-74. PubMed ID: 8771239
[TBL] [Abstract][Full Text] [Related]
52. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.
Goldberg MR; Tanaka W; Barchowsky A; Bradstreet TE; McCrea J; Lo MW; McWilliams EJ; Bjornsson TD
Hypertension; 1993 May; 21(5):704-13. PubMed ID: 8491505
[TBL] [Abstract][Full Text] [Related]
53. Intravenous losartan inhibits the increase in plasma luteinizing hormone and water intake produced by intraventricular angiotensin II.
Palmer AA; Steele MK; Shackelford RL; Ganong WF
Proc Soc Exp Biol Med; 1994 Mar; 205(3):263-6. PubMed ID: 8171048
[TBL] [Abstract][Full Text] [Related]
54. Angiotensin II-induced responses in vascular smooth muscle cells: inhibition by non-peptide receptor antagonists.
Catalioto RM; Porchia R; Renzetti AR; Criscuoli M; Subissi A; Giachetti A
Eur J Pharmacol; 1995 Jul; 280(3):285-92. PubMed ID: 8566096
[TBL] [Abstract][Full Text] [Related]
55. Contribution of the renin-angiotensin and kallikrein-kinin systems to short-term variability of blood pressure in two-kidney, one-clip hypertensive rats.
Ponchon P; Elghozi JL
Eur J Pharmacol; 1996 Feb; 297(1-2):61-70. PubMed ID: 8851167
[TBL] [Abstract][Full Text] [Related]
56. Effect of renal perfusion pressure on renal function, renin release and renin and angiotensinogen gene expression in rats.
Moosavi SM; Johns EJ
J Physiol; 1999 Oct; 520 Pt 1(Pt 1):261-9. PubMed ID: 10517817
[TBL] [Abstract][Full Text] [Related]
57. Evidence for the involvement of different receptor subtypes in the pre- and postjunctional actions of angiotensin II at rat sympathetic neuroeffector sites.
Cox SL; Ben A; Story DF; Ziogas J
Br J Pharmacol; 1995 Mar; 114(5):1057-63. PubMed ID: 7780640
[TBL] [Abstract][Full Text] [Related]
58. Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man.
Doig JK; MacFadyen RJ; Sweet CS; Lees KR; Reid JL
J Cardiovasc Pharmacol; 1993 May; 21(5):732-8. PubMed ID: 7685442
[TBL] [Abstract][Full Text] [Related]
59. Novel angiotensin receptor subtypes in fowl.
Nishimura H; Walker OE; Patton CM; Madison AB; Chiu AT; Keiser J
Am J Physiol; 1994 Nov; 267(5 Pt 2):R1174-81. PubMed ID: 7977843
[TBL] [Abstract][Full Text] [Related]
60. In vitro pharmacology of a nonpeptidic angiotensin II receptor antagonist, SC-51316.
Olins GM; Corpus VM; McMahon EG; Palomo MA; Schuh JR; Blehm DJ; Huang HC; Reitz DB; Manning RE; Blaine EH
J Pharmacol Exp Ther; 1992 Jun; 261(3):1037-43. PubMed ID: 1602371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
